BNP vs NT-proBNP: Key Differences, Normal Levels, and Clinical Interpretation in Heart Failure
BNP and NT-proBNP Tests: What They Mean and How They Are Used in Heart Failure Diagnosis
B-type natriuretic peptide (BNP) and N-terminal pro–B-type natriuretic peptide (NT-proBNP) are two of the most widely used biomarkers in cardiology, especially for diagnosing and assessing heart failure. Both markers originate from the same precursor molecule, yet they differ in biological characteristics and clinical applications. Understanding these differences is essential when interpreting results and making treatment decisions.
1. Where Do BNP and NT-proBNP Come From?
Despite the name “brain” natriuretic peptide, BNP is produced mainly by the heart—specifically from ventricular myocardial cells.
When ventricular wall stress increases due to pressure overload or volume overload, cardiomyocytes release proBNP, which is then cleaved into:
- BNP – the biologically active hormone
- NT-proBNP – an inactive peptide fragment
Both circulate in the bloodstream, and their levels rise proportionally to cardiac stress. This makes them powerful tools for evaluating heart function.
2. BNP vs NT-proBNP: What’s the Difference?
| Feature | BNP | NT-proBNP |
|---|---|---|
| Biochemical nature | Active hormone | Inactive fragment |
| Half-life | ~20 minutes | ~60–120 minutes (longer stability) |
| Stability | Less stable | More stable; preferred in many labs |
| Clinical use | Excellent for acute HF diagnosis | Useful for diagnosis, prognosis, and monitoring |
| Typical cut-off | < 100 pg/mL | < 125 pg/mL |
Because of its longer half-life and stability, NT-proBNP is often favored for routine monitoring and prognostication.
3. Use in Acute Heart Failure
BNP and NT-proBNP are essential for distinguishing cardiac from non-cardiac causes of acute dyspnea in emergency settings.
Common diagnostic thresholds
BNP
- 100 pg/mL → strongly suggests acute heart failure
NT-proBNP
- Age < 50: > 450 pg/mL
- Age 50–75: > 900 pg/mL
- Age > 75: > 1800 pg/mL
These values are widely used in emergency departments due to their high diagnostic accuracy.
4. Assessing Severity and Prognosis
Higher levels of BNP/NT-proBNP are associated with:
- Worse left ventricular function
- Increased cardiac wall stress
- Higher risk of hospitalization
- Increased short-term and long-term mortality
For this reason, natriuretic peptides are central to both acute and chronic heart failure management.
5. Non-Heart Failure Causes of Elevated BNP/NT-proBNP
While highly useful, these markers may increase in several non-cardiac conditions:
- Atrial fibrillation or other tachyarrhythmias
- Acute myocardial infarction
- Chronic kidney disease (especially NT-proBNP)
- Pulmonary hypertension or pulmonary embolism
- COPD exacerbations
- Sepsis or systemic inflammation
- Advanced age
- Thyroid dysfunction
Understanding these confounders is important when interpreting borderline or unexpected results.
6. What If Levels Are Normal?
A low BNP or NT-proBNP level virtually rules out acute heart failure.
- BNP < 100 pg/mL
- NT-proBNP < 125 pg/mL
These values have a very high negative predictive value, making natriuretic peptides especially useful in emergency triage.
7. Choosing Between BNP and NT-proBNP
BNP
- Shorter half-life
- Quickly responsive to acute changes
- Useful in ED settings
NT-proBNP
- More stable
- Better for long-term monitoring
- Less affected by obesity
- Strong prognostic value
The choice often depends on institutional preference, patient age, renal function, and the clinical question.
Conclusion
BNP and NT-proBNP are essential biomarkers that directly reflect cardiac stress and function. They guide the diagnosis of acute heart failure, assess disease severity, monitor treatment response, and predict prognosis. Despite differences in stability and interpretation, both markers remain indispensable in modern cardiology.
References
- Maisel A, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med.
- Januzzi JL, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure. J Am Coll Cardiol.
- Yancy CW, et al. 2017 ACC/AHA/HFSA Focused Update of the Heart Failure Guidelines.
- McCullough PA, et al. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Am J Med.
- Ponikowski P, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016).
- Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol.